Market evolution: Artificial body parts (CN 902139) — 2015–2025

Introduction

This report examines the evolution of EU trade in artificial body parts (excluding artificial teeth, dental fittings, and artificial joints) under customs code 902139 over the period 2015–2025. The product scope covers ocular prostheses (CN 90213910) and a broader residual category of other artificial body parts (CN 90213990), encompassing items such as cardiac valves, artificial limbs, and similar medical devices not elsewhere classified. Over the decade under review, the EU market for these products underwent a profound structural transformation: the bloc evolved from a modest net importer into a strongly export-oriented sector, underpinned by rapid production growth and deepening integration into global supply chains.

1. From Net Importer to Net Exporter: A Decade of Structural Rebalancing

The EU's trade balance swung dramatically in favour of exports

The single most striking dynamic in the decade under review is the reversal of the EU's net trade position. In 2015, the EU recorded a trade surplus of just €268 million with the rest of the world. By 2025, this surplus had expanded to €768 million—an increase of 186.4%. The net import reliance indicator captures this shift vividly: it moved from +11.3% in 2015 to −23.8% in 2025, meaning the EU went from depending on external suppliers to generate a modest share of domestic consumption to being a significant net exporter to the rest of the world.

Export growth outpaced import growth in both value and volume

While both exports and imports grew in value over the period, the nature of that growth differed fundamentally. Export values rose by 83.7% and export volumes by 51.0%, indicating that the EU was both selling more units abroad and commanding higher prices per unit. Import values grew by 68.2%, but import volumes actually contracted by 2.7%—from 2,721 tonnes in 2015 to 2,649 tonnes in 2025. This implies that the rise in import values was almost entirely driven by price increases: import unit values surged by 74.0% (from €641,275/t to €1,115,986/t), far outstripping the 22.5% rise in export unit values (from €748,311/t to €917,008/t).

This price divergence is significant. It suggests that the EU's import basket shifted toward higher-value, more specialised products—or that suppliers to the EU gained pricing power over the decade—while EU exporters competed more on volume and cost efficiency.

Domestic production expanded dramatically

The EU's manufacturing base in this sector grew at an exceptional pace. According to PRODCOM production data, production value rose from approximately €978 million in the earliest available year to an estimated €4.0 billion by the end of the period—a staggering increase of 309.2%. This expansion of domestic capacity is the primary engine behind the EU's improved trade balance and its growing export propensity. The export propensity (exports as a share of production) rose from 34.5% to 92.0%, indicating that an increasingly large share of EU output was destined for external markets.

2. Geographic Diversification and Shifting Partner Dynamics

Import sources diversified substantially

At the start of the period, EU imports of artificial body parts were heavily concentrated on a small number of suppliers, with a Herfindahl–Hirschman Index (HHI) of 4,860—well above the threshold typically considered indicative of a highly concentrated market. By 2025, the HHI had fallen to 3,083, a decline of 36.6%. This means the EU's import supply base became meaningfully more diversified over the decade.

The United States remained the dominant import partner, accounting for €1.54 billion in 2025 (+26.6% vs. 2015). However, its share in total imports eroded as several other partners grew much faster:

The most dramatic growth came from China (+1,400%), Iceland (+548%), and Costa Rica (+335%). The surge in imports from Costa Rica and Singapore may partly reflect the routing of goods through logistics or manufacturing hubs, while the growth from China and Mexico points to the increasing role of emerging-market producers in this sector.

Export destinations broadened, led by the UK and emerging markets

On the export side, the EU's customer base also expanded. The United Kingdom became the largest single export destination, with exports rising from €187 million to €509 million (+171.8%)—a trend likely reinforced by post-Brexit trade dynamics requiring direct bilateral flows rather than intra-EU circulation. Exports to Russia grew by 205%, to Turkey by 149%, and to China by 112%, reflecting the EU's role as a supplier of advanced medical devices to fast-growing healthcare markets.

Notably, exports to the United States—the EU's second-largest destination—actually declined slightly (−4.7%), suggesting that the US market may have become more competitive or that EU producers redirected output toward other growing markets.

The Netherlands emerged as the EU's dominant trade hub

Within the EU, the Netherlands consolidated its position as the single most important member state for both imports and exports of artificial body parts. Dutch imports rose from €726 million to €2.04 billion (+181.5%), while exports grew from €878 million to €1.64 billion (+86.4%). The Netherlands' RCA (Revealed Comparative Advantage) of 4.08 and its high specialisation score (RSCA of 0.61) in 2025 confirm its strong competitive position. Belgium and Germany followed as the next-largest traders, with Belgium's exports more than tripling (+222%) and Germany's rising by 72%.

3. Volatility, Price Shocks, and Evolving Supply Risks

Import supply chains showed moderate to high volatility

The coefficient of variation (CV) of import flows varied significantly across partners, revealing differing degrees of supply predictability. The United States, as the largest supplier, exhibited relatively low volatility (CV of 0.13), confirming its role as a stable anchor of EU supply. By contrast, several smaller but fast-growing suppliers displayed much higher variability:

This pattern suggests that while the EU successfully diversified its import sources, many of the new suppliers introduced greater year-to-year variability. For critical medical devices, this trade-off between diversification and reliability warrants careful monitoring.

Notable price shocks clustered around 2019–2020

The shock detection analysis identified several abnormal price events, notably clustering around 2019–2020:

The Costa Rica price shock is particularly noteworthy given that Costa Rica accounted for 12% of EU import value by 2025. The 121% price spike in 2020—coinciding with the onset of the COVID-19 pandemic—likely reflects supply chain disruptions, surging demand for medical devices, or shifts in the product mix being shipped through that corridor. The Colombia and Norway events, while smaller in absolute market share, further illustrate the turbulence that characterised this sector around the pandemic period.

EU production growth has reduced structural vulnerability

Despite the volatility observed in individual supply relationships, the overarching trend in EU autonomy has been positive. The shift from positive net import reliance (+11.3%) to strongly negative net import reliance (−23.8%) means that the EU now produces significantly more than it consumes domestically in this category. The dramatic rise in trade intensity (from 55.5% to 95.4%) and export propensity (from 34.5% to 92.0%) underscores that the EU has become deeply embedded in global value chains for these products—not as a dependent importer, but as a competitive exporter.

Conclusion

Over the 2015–2025 period, the EU market for artificial body parts (CN 902139) underwent a fundamental transformation. The bloc transitioned from a modest net importer with a narrow supplier base to a major net exporter with a diversified and growing trade footprint. This shift was driven by a near-quadrupling of domestic production value, which enabled the EU to serve both its own market and expanding global demand—particularly in the UK, China, Turkey, Russia, and India.

At the same time, the import side experienced significant price inflation (+74% in unit values) while volumes remained essentially flat, suggesting a qualitative shift in what the EU imports—potentially toward more specialised or high-tech components. The import supply base diversified considerably (HHI down 37%), though several newer suppliers exhibited high volatility, and pandemic-era price shocks highlighted the fragility of certain trade corridors.

Looking ahead, the EU's strong and improving competitive position in this sector—led by the Netherlands, Belgium, and Germany—provides a solid foundation. However, the concentration of production in a small number of member states, the reliance on a few high-volatility import partners for residual needs, and the geopolitical sensitivities surrounding medical devices all represent areas for continued attention by policymakers and industry stakeholders.